EDP 420

Drug Profile

EDP 420

Alternative Names: EDP-420; EP-013420; EP-13420; S-013420

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enanta Pharmaceuticals
  • Developer Enanta Pharmaceuticals; Shionogi
  • Class Antibacterials; Macrolides; Organic bridged compounds
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Community-acquired pneumonia; Helicobacter infections; Mycobacterium avium complex infections; Respiratory tract infections; Skin and soft tissue infections; Tuberculosis

Most Recent Events

  • 25 May 2010 Discontinued - Phase-II for Respiratory tract infections in Japan (PO)
  • 28 Oct 2008 Preclinical trials in Skin and soft tissue infections in USA (PO)
  • 28 Oct 2008 Preclinical pharmacodynamics data presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America (ICAAC/IDSA-2008) ,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top